A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
Chondrosarcoma
DRUG: PRO95780
Adverse events|Change in vital signs before and after PRO95780 infusions; clinical laboratory evaluations|Objective response
Duration of objective response|Progression-free survival|Overall survival|Pharmacokinetic parameters
This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.